DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2

Not yet recruiting

Conditions: Esophageal Squamous Cell Carcinoma

Interventions: Drug: placebo+PD-1+chemo
Drug: ATRA+pd-1+chemo

First Posted Date: 2024-11-25

Last Posted Date: 2024-11-25

Lead Sponsor: Fudan University

Target Recruit Count: 180

Registration Number: NCT06703047

A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib

Phase 2

Recruiting

Conditions: Ewing Sarcoma
Myelosuppression

Interventions: Drug: Chemotherapy
Drug: Trilaciclib Injection [Cosela]

First Posted Date: 2024-11-21

Last Posted Date: 2024-11-21

Lead Sponsor: Fudan University

Target Recruit Count: 22

Registration Number: NCT06699472

Locations: 🇨🇳
Fudan University Shanghai Cencer Center,, Shanghai, Shanghai, China

First-line Treatment of Advanced/unresectable DDLPS

Phase 2

Not yet recruiting

Conditions: Dedifferentiated Liposarcoma
Soft Tissue Sarcoma (STS)

Interventions: Drug: Liposomal Doxorubicin (Doxil)
Drug: Apatinib
Drug: Camrelizumab

First Posted Date: 2024-11-19

Last Posted Date: 2024-11-19

Lead Sponsor: Fudan University

Target Recruit Count: 49

Registration Number: NCT06694324

Locations: 🇨🇳
Fudan University, Cancer Hospital, Shanghai, Shanghai, China

Combination of Toripalimab and JS004 Therapy for ccRCC

Phase 2

Recruiting

Conditions: Clear Cell Renal Cell Carcinoma

Interventions: Drug: Axitinib
Drug: JS004
Drug: Sorafenib
Drug: Toripalimab

First Posted Date: 2024-11-15

Last Posted Date: 2024-11-15

Lead Sponsor: Fudan University

Target Recruit Count: 80

Registration Number: NCT06690697

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors

Phase 2

Recruiting

Conditions: Paget Disease, Extramammary
Rhabdomyosarcoma
Testicular Cancer
Penile Cancer
Urachal Cancer

Interventions: Drug: Albumin-paclitaxel Injection

First Posted Date: 2024-11-12

Last Posted Date: 2024-12-20

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT06684327

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Ivocizumab in the Treatment of Multiple Advanced Tumors

Phase 2

Recruiting

Conditions: Pheochromocytoma/Paraganglioma
Paget Disease, Extramammary
Renal Angiomyolipoma
Rhabdomyosarcoma
Perivascular Epithelioid Cell Tumor, Malignant
Sarcoma
Urachal Cancer
Neuroendocrine Cancer
Basal Cell Carcinomas
Sarcomatoid Carcinoma

Interventions: Drug: Ivocizumab

First Posted Date: 2024-11-12

Last Posted Date: 2024-12-27

Lead Sponsor: Fudan University

Target Recruit Count: 400

Registration Number: NCT06683846

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung Cancer

Recruiting

Conditions: NSCLC (Non-small Cell Lung Cancer)
Artificial Intelligence (AI)
Lymphnode Metastasis

First Posted Date: 2024-11-12

Last Posted Date: 2025-01-20

Lead Sponsor: Fudan University

Target Recruit Count: 6000

Registration Number: NCT06684418

Locations: 🇨🇳
Fudan university Shanghai Cancer Center, Shanghai, China

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

Not Applicable

Recruiting

Conditions: Treatment
Neoantigen
Vaccine
Solid Tumor Cancer

Interventions: Drug: DC Vaccine

First Posted Date: 2024-11-12

Last Posted Date: 2024-11-19

Lead Sponsor: Fudan University

Target Recruit Count: 9

Registration Number: NCT06682117

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

SHR-1701 Combined with SHR2554 and BP102 for MCRC

Phase 2

Not yet recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: SHR-1701
Drug: BP102
Drug: SHR2554

First Posted Date: 2024-11-07

Last Posted Date: 2024-11-07

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06679673

Locations: 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Caner Center, Shanghai, Shanghai, China

TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

Phase 3

Recruiting

Conditions: Esophageal Carcinoma
Radiotherapy
Immunotherapy

Interventions: Drug: Immunotherapy
Radiation: TDLN-sparing RT

First Posted Date: 2024-11-06

Last Posted Date: 2024-11-07

Lead Sponsor: Fudan University

Target Recruit Count: 432

Registration Number: NCT06676449

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy